Get the Stockscreener App
6.22
2.64%
0.16
After Hours:
6.33
0.11
+1.77%
Savara Inc stock is traded at $6.22, with a volume of 1.53M.
It is up +2.64% in the last 24 hours and up +18.48% over the past month.
Savara Inc is a clinical-stage biopharmaceutical company. It is focused on rare respiratory diseases. It has one segment specialty pharmaceuticals within the respiratory system. The company's main product candidate, molgramostim, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).
See More
Previous Close:
$6.06
Open:
$6.1
24h Volume:
1.53M
Relative Volume:
0.99
Market Cap:
$1.27B
Revenue:
-
Net Income/Loss:
$-129.48M
P/E Ratio:
-11.14
EPS:
-0.5584
Net Cash Flow:
$-106.97M
1W Performance:
+3.15%
1M Performance:
+18.48%
6M Performance:
+10.28%
1Y Performance:
+196.19%
1-Day Range:
$6.07
$6.26
1-Week Range:
$5.715
$6.2898
52-Week Range:
$2.10
$7.005
Savara Inc Stock (SVRA) Company Profile
Name
Savara Inc
Sector
Industry
Phone
51285113796
Address
6836 BEE CAVE ROAD, AUSTIN, TX
Compare SVRA vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SVRA
Savara Inc
|
6.22 | 1.26B | 0 | -129.48M | -106.97M | -0.5584 |
VRTX
Vertex Pharmaceuticals Inc
|
528.04 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
654.27 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
939.68 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
312.78 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.24 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
Savara Inc Stock (SVRA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-24-26 | Resumed | Oppenheimer | Outperform |
| Oct-20-25 | Initiated | Wells Fargo | Overweight |
| Aug-15-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| May-29-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Dec-20-24 | Initiated | Wells Fargo | Overweight |
| Nov-13-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Feb-15-24 | Initiated | JMP Securities | Mkt Outperform |
| Nov-07-23 | Initiated | Guggenheim | Buy |
| May-16-23 | Upgrade | Jefferies | Hold → Buy |
| Mar-31-23 | Downgrade | Jefferies | Buy → Hold |
| Mar-16-21 | Initiated | Piper Sandler | Overweight |
| Mar-15-21 | Initiated | Oppenheimer | Outperform |
| Jun-13-19 | Reiterated | H.C. Wainwright | Buy |
| Jun-13-19 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Jun-13-19 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Aug-13-18 | Resumed | ROTH Capital | Neutral |
| Jan-03-18 | Initiated | Ladenburg Thalmann | Buy |
| Sep-27-17 | Resumed | ROTH Capital | Buy |
| Sep-22-17 | Initiated | Jefferies | Buy |
| Sep-11-17 | Initiated | JMP Securities | Mkt Outperform |
View All
Savara Inc Stock (SVRA) Latest News
Price to sales forward of Savara, Inc. – NASDAQ:SVRA - TradingView
Enterprise value to revenue forward of Savara, Inc. – NASDAQ:SVRA - TradingView
Savara Inc. (SVRA) Class Action Lawsuit: Levi & Korsinsky Reminds Investors of November 7, 2025 Deadline - The National Law Review
Securities Lawsuit Alert: Savara Inc. (SVRA) InvestorsContact Levi & Korsinsky Before November 7, 2025 - The National Law Review
Class Action Lawsuit Alert: Levi & Korsinsky Reminds Savara Inc. (SVRA) Investors of November 7, 2025 Deadline - The National Law Review
SVRA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
Levi & Korsinsky Notifies Savara Inc. (SVRA) InvestorsLead Plaintiff Deadline on November 7, 2025 - The National Law Review
Investors SueWallSt as Savara Inc. Faces Securities Fraud Allegations - The National Law Review
Investors in Savara Inc. (SVRA): Protect Your RightsContact Levi & Korsinsky Before November 7, 2025 - The National Law Review
Savara, Inc. Actuals & Estimates (FWB:YB4P) - TradingView
SVRA Forecast — Price Target — Prediction for 2027 - TradingView
What Does the FDA's Priority Review Mean for Savara's MOLBREEVI - Kavout | AI
Savara, Inc. Actuals & Estimates (SWB:YB4P) - TradingView
YB4P Forecast — Price Target — Prediction for 2027 - TradingView
Savara Inc (SVRA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Savara CFO David Lowrance sells $2.24m in company stock By Investing.com - Investing.com Australia
Savara CFO David Lowrance sells $2.24m in company stock - Investing.com UK
Form 4 Savara Inc For: 22 June By Investing.com - Investing.com Nigeria
Savara (SVRA) CFO exercises 580K options and sells 394K shares in Form 4 - Stock Titan
Form 144 Savara Inc For: 22 June By Investing.com - Investing.com South Africa
[144] Savara Inc SEC Filing - Stock Titan
Does Savara’s Expanded Share Pool and CFO Shift Reframe Its Capital Strategy Narrative (SVRA)? - simplywall.st
Savara StockLong-term pipeline story in rare lung disease - AD HOC NEWS
Savara Grants Equity Awards to New Hires Amid Growth Push - MyChesCo
Savara Inc (SVRA) Valuation: PE, PB & Fair Value Analysis - TradingKey
Savara Inc (SVRA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Savara Shifts Finance Leadership Ahead of Key Drug Milestone - MyChesCo
Savara Inc (SVRA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Savara Inc (SVRA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Savara Inc (SVRA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Savara Inc (SVRA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Savara Inc (SVRA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Savara Inc (SVRA) Institutional Confidence - TradingKey
Savara (SVRA) Proxy filing Summary - Quartr
What Is Driving Attention Toward Savara’s Rare Disease Strategy? - Kalkine Media
Savara: Lowrance Will Remain Available in Advisory Capacity >SVRA - Moomoo
Savara Announces New Employment Inducement Grant - Business Wire
How Investors Are Reacting To Savara (SVRA) Doubling Share Authorization And Reshaping Its CFO Role - simplywall.st
Savara shareholders approve share increases and executive changes at annual meeting - Investing.com Australia
Savara (SVRA) Announces Leadership Changes in Finance Department - GuruFocus
Savara shareholders approve share increases and executive changes at annual meeting By Investing.com - Investing.com South Africa
Savara Expands Share Capital and Updates Executive Leadership - TipRanks
symbol__ Stock Quote Price and Forecast - CNN
Savara CFO Dave Lowrance steps down; COO Robert Lutz takes on CFO role amid leadership reshuffle - Pluang
Savara Inc Stock (SVRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Savara Inc Stock (SVRA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Lowrance David L | Chief Financial Officer |
Jun 22 '26 |
Sale |
5.68 |
394,528 |
2,241,432 |
536,032 |
3.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):